查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087577

脊髓性肌肉萎縮症治療市場：2026-2032年全球市場預測（依疾病類型、治療類型、給藥途徑、最終用戶和通路分類）

Spinal Muscular Atrophy Treatment Market by Disease Type, Treatment Type, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，脊髓性肌肉萎縮症治療市場規模將達到 100.8 億美元，複合年成長率為 10.97%。

主要市場統計數據
基準年 2025 48.6億美元
預計年份：2026年 53.6億美元
預測年份 2032 100.8億美元
複合年成長率 (%) 10.97%

脊髓性肌肉萎縮症（SMA）的治療正從症狀治療轉向疾病修正治療，使其成為罕見神經肌肉疾病精準醫學領域最重要的研究方向之一。 SMA主要由SMN1基因的雙等位基因缺失或突變引起，疾病的嚴重程度取決於SMN2基因的拷貝數。流行病學文獻普遍通報，SMA的發生率約為每6000至10000例新生兒中出現1例，早期診斷和及時治療是改善臨床預後的關鍵。

目前，治療主要依靠三種已核准的疾病修正治療：nusinersen，一種鞘內注射的反義寡核苷酸，於2016年首次獲得美國FDA批准；onasemnogen abeparvovec，一種基於AAV9的基因替代療法，於2019年首次獲得批准；以及lisdipram，一種口服SMN2剪接調節劑，於2020年首次獲得批准。這些療法正在改變患者的生存率、運動發展階段的達成情況以及長期護理計劃，同時也提高了新生兒篩檢、遺傳諮詢、保險公司證據以及上市後安全性監測的重要性。

SMA治療前景的突破性改變。

脊髓性肌肉萎縮症（SMA）治療前景最顯著的轉變在於，治療應在症狀出現前進行。臨床和真實世界證據一致表明，在運動神經元不可逆性損傷發生前接受治療的患者，其功能預後通常優於症狀出現後接受治療的患者。這使得新生兒篩檢成為一項重要的策略性舉措，尤其是在那些已將SMA納入國家和地區篩檢目標的國家和醫療體系中。

人工智慧在脊髓性肌肉萎縮症治療中的累積影響

人工智慧 (AI) 正日益成為脊髓性肌肉萎縮症 (SMA) 診斷、治療監測和整體市場進入的重要驅動力。在臨床護理中，AI 驅動的分析可以幫助早期識別運動發育遲緩，最佳化基因檢測流程，並分析來自穿戴式裝置和基於影片的運動功能評估的數位生物標記。這些應用尤其重要，因為治療時機是 SMA 預後的關鍵決定因素。

全球SMA治療市場的關鍵區域洞察

北美地區在脊髓性肌肉萎縮症（SMA）治療的推廣方面仍處於主導地位，這得益於其完善的新生兒篩檢、高密度的專科醫生、成熟的保險體係以及早期獲得FDA批准療法的機會。尤其值得一提的是，自2018年SMA被納入「推薦統一篩檢計畫」以來，美國在SMA治療領域發揮了顯著作用，推動了更廣泛的無症狀診斷。在加拿大，各省的保險覆蓋政策和由專科醫生主導的神經肌肉診療網路也在不斷擴大SMA的治療覆蓋範圍。

基於關鍵族群的SMA治療推廣分析

由於七國集團（G7）擁有高額的醫療保健支出、先進的監管體係以及完善的罕見疾病保險報銷機制，它們在脊髓性肌肉萎縮症（SMA）治療藥物的商業化進程中繼續發揮著核心作用。美國、加拿大、日本、德國、法國、義大利和英國正在塑造高成本療法（包括基因療法和慢性SMN2標靶治療）的臨床證據、註冊登記設計以及保險公司報銷標準的預期。

深入了解影響 SMA 治療需求的關鍵國家。

美國是脊髓性肌肉萎縮症（SMA）治療領域最具影響力的市場，這得益於其早期核准、新生兒篩檢的廣泛實施，以及由神經肌肉疾病中心、患者權益組織和專科藥房組成的大規模生態系統。加拿大雖然規模較小，但其高度結構化的醫療環境由各省的健保報銷制度和專家共識共同塑造。墨西哥和巴西則代表拉丁美洲重要的醫療資源取得機會，在這些地區，治療的可及性取決於公共資金、私人保險覆蓋範圍以及針對高成本罕見疾病治療的法律和政策機制。

為SMA產業領導者提供的實用建議

產業領導者應優先考慮早期診斷，具體措施包括擴大新生兒篩檢、建立權威的基因檢測系統，以及支持小兒科、神經科和遺傳學領域的臨床醫生接受相關教育。由於脊髓性肌肉萎縮症 (SMA) 的預後與時間密切相關，因此縮短從出生到確診和開始治療的時間對於維持治療至關重要。

SMA治療分析的調查方法

本執行摘要基於二手研究，採用經核實的公開資料，包括法規核准文件、同行評審的流行病學和臨床文獻、新生兒篩檢政策參考資料、衛生技術評估趨勢以及資訊來源。本檢驗著重於資料支持的趨勢，而非推測性的論斷。

結論：SMA治療的未來

脊髓性肌肉萎縮症（SMA）的治療模式已進入一個更為複雜的階段，其特點是需要早期診斷、多樣化的治療方案、支付方的嚴格審查以及永續的真實世界證據。疾病修正治療已改變了SMA的臨床進程，但不同地區和收入水平的患者在獲得治療方面仍然存在差距。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 脊髓性肌肉萎縮症治療市場：依疾病類型分類

  • 1 型 SMA
  • 2 型 SMA
  • 3 型 SMA
  • 4 型 SMA

第8章 脊髓性肌肉萎縮症治療市場：依治療類型分類

  • 基因治療
  • 藥物治療
    • 努西納森
    • 莉茲·迪普拉姆

第9章 脊髓性肌肉萎縮症治療市場：依給藥途徑分類

  • 口服
  • 鞘內給藥
  • 靜脈

第10章 脊髓性肌肉萎縮症治療市場：依最終使用者分類

  • 居家照護環境
  • 醫院
  • 專科診所
  • 神經科中心
  • 研究機構

第11章 脊髓性肌肉萎縮症治療市場：依通路分類

  • 網路藥房
  • 物理藥房

第12章 脊髓性肌肉萎縮症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 脊髓性肌肉萎縮症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 脊髓性肌肉萎縮症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Astellas Pharma Inc
  • Biogen Inc
  • Biohaven Ltd
  • Chugai Pharmaceutical Co Ltd
  • Cytokinetics Inc
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals Inc
  • Natco Pharma
  • NMD Pharma A/S
  • Novartis AG
  • Pfizer Inc
  • PTC Therapeutics Inc
  • REGENXBIO Inc
  • Sarepta Therapeutics Inc
  • Scholar Rock Inc
  • Shionogi & Co Ltd
  • Vertex Pharmaceuticals Inc
Product Code: MRR-0309FBC512FA

The Spinal Muscular Atrophy Treatment Market is projected to grow by USD 10.08 billion at a CAGR of 10.97% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.86 billion
Estimated Year [2026] USD 5.36 billion
Forecast Year [2032] USD 10.08 billion
CAGR (%) 10.97%

Spinal muscular atrophy treatment has shifted from supportive management to disease-modifying intervention, creating one of the most important precision-medicine areas in rare neuromuscular care. SMA is most commonly caused by biallelic loss or mutation of the SMN1 gene, with disease severity influenced by SMN2 copy number. Epidemiologic literature commonly reports SMA incidence at roughly 1 in 6,000 to 1 in 10,000 live births, making early diagnosis and timely therapy central to clinical outcomes.

The treatment landscape is anchored by three approved disease-modifying options: nusinersen, an intrathecal antisense oligonucleotide first approved by the U.S. FDA in 2016; onasemnogene abeparvovec, an AAV9-based gene replacement therapy first approved in 2019; and risdiplam, an oral SMN2 splicing modifier first approved in 2020. These therapies have redefined survival, motor milestone achievement, and long-term care planning, while also elevating the importance of newborn screening, genetic counseling, payer evidence, and post-marketing safety monitoring.

Transformative Shifts in the SMA Treatment Landscape

The most significant shift in the SMA treatment landscape is the move toward presymptomatic treatment. Clinical and real-world evidence consistently shows that patients treated before irreversible motor neuron loss generally achieve better functional outcomes than those treated after symptom onset. This has made newborn screening a strategic enabler, particularly in countries and health systems that have added SMA to national or regional screening panels.

Another transformative shift is the transition from single-product decision-making to lifecycle treatment strategy. Clinicians, payers, and families are increasingly evaluating route of administration, durability of response, safety profile, age and weight eligibility, intrathecal access, oral adherence, and the evidence base for switching or sequencing therapies. Manufacturers must therefore compete not only on efficacy, but also on long-term outcomes, access support, registry evidence, and value demonstration.

Cumulative Impact of Artificial Intelligence on SMA Treatment

Artificial intelligence is becoming a practical accelerator across SMA diagnosis, treatment monitoring, and market access. In clinical care, AI-enabled analytics can support earlier identification of delayed motor milestones, prioritize genetic testing workflows, and analyze digital biomarkers from wearables or video-based motor assessments. These applications are especially relevant because treatment timing is a major determinant of outcome in SMA.

For health systems, AI is improving real-world evidence generation by structuring registry data, identifying treatment-response patterns, and supporting pharmacovigilance signal detection. In market access, predictive modeling can help assess patient identification pathways, care burden, and long-term outcomes, provided models remain transparent, clinically validated, and compliant with privacy and health-data governance requirements.

Key Regional Insights Across Global SMA Treatment Markets

North America remains a leading region for SMA treatment adoption due to established newborn screening, high specialist density, mature payer infrastructure, and early availability of FDA-approved therapies. The United States has been especially influential because SMA was added to the Recommended Uniform Screening Panel in 2018, supporting broader presymptomatic diagnosis. Canada continues to expand access through provincial reimbursement decisions and specialist-led neuromuscular networks.

Europe is characterized by strong regulatory oversight through the European Medicines Agency and country-specific reimbursement pathways that assess clinical value, budget impact, and long-term evidence. The European Union benefits from cross-border rare disease collaboration, while the United Kingdom, Germany, France, Italy, and Spain remain important treatment and evidence-generation markets. Asia-Pacific is expanding as Japan, Australia, South Korea, China, and India increase genetic testing capacity, rare disease policy attention, and access to disease-modifying therapies.

Latin America, the Middle East, and Africa present important but uneven-access environments. Brazil and Mexico anchor Latin American demand, while Middle Eastern countries, particularly in the GCC, are investing in genomic medicine, newborn screening, and advanced therapies. In Africa, access is constrained by diagnostic infrastructure, affordability, and specialist availability, but newborn screening pilots, philanthropic programs, and regional rare disease advocacy are creating a foundation for future treatment access.

Key Group Insights for SMA Treatment Adoption

The G7 markets remain central to SMA treatment commercialization because they combine high healthcare expenditure, advanced regulatory systems, and established rare disease reimbursement frameworks. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom shape clinical evidence expectations, registry design, and payer standards for high-cost therapies, including gene therapy and chronic SMN2-targeted treatment.

The European Union provides a coordinated regulatory environment and growing rare disease data infrastructure, but reimbursement remains country-specific and frequently tied to health technology assessment outcomes. BRICS countries offer major long-term treatment-access potential because of large birth cohorts and expanding genetic medicine capabilities, although affordability, reimbursement variability, and unequal diagnostic coverage remain critical barriers.

ASEAN markets are progressing through specialist-center development and selective access programs, with adoption depending heavily on public funding and diagnostic reach. GCC countries are prioritizing genomics, newborn screening, and tertiary care investment, creating a favorable environment for advanced SMA therapies. NATO is not a healthcare market, but its member economies include many strong rare disease systems, supporting supply-chain resilience, regulatory alignment, and clinical research collaboration.

Key Country Insights Shaping SMA Treatment Demand

The United States is the most influential SMA treatment market due to early approvals, broad newborn screening adoption, and a large ecosystem of neuromuscular centers, patient advocacy organizations, and specialty pharmacies. Canada has a smaller but highly structured environment shaped by provincial reimbursement and specialist consensus. Mexico and Brazil represent important Latin American access opportunities, with treatment availability dependent on public-sector funding, private insurance coverage, and legal or policy mechanisms for high-cost rare disease therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established pathways for SMA therapy access, although reimbursement criteria can differ by age, SMA type, functional status, and evidence requirements. Russia has domestic rare disease policy mechanisms but faces procurement and access variability. China is scaling rare disease policy, genetic testing, and inclusion mechanisms, while India combines substantial unmet need with affordability challenges and growing genetic diagnostics capacity.

Japan, Australia, and South Korea are mature Asia-Pacific markets with advanced regulatory systems and specialist neuromuscular care. Japan has been an early adopter of innovative rare disease therapies, Australia benefits from newborn screening expansion and public reimbursement review processes, and South Korea continues to strengthen access through national insurance assessment and tertiary-care concentration.

Actionable Recommendations for SMA Industry Leaders

Industry leaders should prioritize earlier diagnosis by supporting newborn screening expansion, confirmatory genetic testing capacity, and clinician education across pediatrics, neurology, and genetics. Because SMA outcomes are highly time-sensitive, sustainable adoption depends on shortening the pathway from birth to diagnosis to treatment initiation.

Organizations should invest in long-term real-world evidence, including motor function, respiratory outcomes, survival, caregiver burden, treatment persistence, safety, and health-economic endpoints. Access strategies should be tailored to each market's reimbursement model, with outcomes-based agreements, registries, and patient support programs used where appropriate. Leaders should also build resilient manufacturing and cold-chain capabilities for advanced therapies while maintaining transparent communication around safety monitoring and treatment durability.

Research Methodology for SMA Treatment Analysis

This executive summary is based on secondary research of verified public sources, including regulatory agency approvals, peer-reviewed epidemiology and clinical literature, newborn screening policy references, health technology assessment trends, and publicly available rare disease access information. The analysis emphasizes data-backed developments rather than speculative claims.

The methodology combines disease epidemiology, treatment approval history, regional access assessment, policy review, and qualitative market interpretation. Key analytical variables include approved therapy availability, newborn screening maturity, reimbursement readiness, specialist infrastructure, genetic testing capacity, real-world evidence generation, and health-system affordability.

Conclusion: The Future of SMA Treatment

The SMA treatment landscape is entering a more complex phase defined by earlier diagnosis, multiple therapeutic modalities, payer scrutiny, and demand for durable real-world evidence. Disease-modifying therapies have changed the clinical trajectory of SMA, but access remains uneven across regions and income levels.

Future competitive advantage will depend on evidence depth, speed of diagnosis, treatment personalization, and sustainable reimbursement. Organizations that align clinical innovation with newborn screening, data infrastructure, patient support, and regional access strategies will be best positioned to advance global spinal muscular atrophy treatment access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Spinal Muscular Atrophy Treatment Market, by Disease Type

  • 7.1. Type 1 SMA
  • 7.2. Type 2 SMA
  • 7.3. Type 3 SMA
  • 7.4. Type 4 SMA

8. Spinal Muscular Atrophy Treatment Market, by Treatment Type

  • 8.1. Gene Therapy
  • 8.2. Drug Therapy
    • 8.2.1. Nusinersen
    • 8.2.2. Risdiplam

9. Spinal Muscular Atrophy Treatment Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Intrathecal
  • 9.3. Intravenous

10. Spinal Muscular Atrophy Treatment Market, by End User

  • 10.1. Homecare Settings
  • 10.2. Hospitals
  • 10.3. Specialty Clinics
  • 10.4. Neurology Centers
  • 10.5. Research Institutes

11. Spinal Muscular Atrophy Treatment Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Offline Pharmacies

12. Spinal Muscular Atrophy Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Spinal Muscular Atrophy Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Spinal Muscular Atrophy Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Astellas Pharma Inc
  • 16.2. Biogen Inc
  • 16.3. Biohaven Ltd
  • 16.4. Chugai Pharmaceutical Co Ltd
  • 16.5. Cytokinetics Inc
  • 16.6. F. Hoffmann-La Roche AG
  • 16.7. Ionis Pharmaceuticals Inc
  • 16.8. Natco Pharma
  • 16.9. NMD Pharma A/S
  • 16.10. Novartis AG
  • 16.11. Pfizer Inc
  • 16.12. PTC Therapeutics Inc
  • 16.13. REGENXBIO Inc
  • 16.14. Sarepta Therapeutics Inc
  • 16.15. Scholar Rock Inc
  • 16.16. Shionogi & Co Ltd
  • 16.17. Vertex Pharmaceuticals Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TYPE 1 SMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 1 SMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 1 SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 2 SMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 2 SMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 2 SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 3 SMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 3 SMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 3 SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 4 SMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 4 SMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 4 SMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUSINERSEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUSINERSEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUSINERSEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RISDIPLAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RISDIPLAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RISDIPLAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)